MT1-MMP Initiates Activation of pro-MMP-2 and Integrin αvβ3 Promotes Maturation of MMP-2 in Breast Carcinoma Cells

We evaluated cellular mechanisms involved in the activation pathway of matrix prometalloproteinase-2 (pro-MMP-2), an enzyme implicated in the malignant progression of many tumor types. Membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves the N-terminal prodomain of pro-MMP-2 thus generating the activation intermediate that then matures into the fully active enzyme of MMP-2. Our results provide evidence on how a collaboration between MT1-MMP and integrin alphavbeta3 promotes more efficient activation and specific, transient docking of the activation intermediate and, further, the mature, active enzyme of MMP-2 at discrete regions of cells. We show that coexpression of MT1-MMP and integrin alphavbeta3 in MCF7 breast carcinoma cells specifically enhances in trans autocatalytic maturation of MMP-2. The association of MMP-2's C-terminal hemopexin-like domain with those molecules of integrin alphavbeta3 which are proximal to MT1-MMP facilitates MMP-2 maturation. Vitronectin, a specific ligand of integrin alphavbeta3, competitively blocked the integrin-dependent maturation of MMP-2. Immunofluorescence and immunoprecipitation studies supported clustering of MT1-MMP and integrin alphavbeta3 at discrete regions of the cell surface. Evidently, the identified mechanisms appear to be instrumental to clustering active MMP-2 directly at the invadopodia and invasive front of alphavbeta3-expressing cells or in their close vicinity, thereby accelerating tumor cell locomotion.

[1]  C. Overall,et al.  Domain Interactions in the Gelatinase A·TIMP-2·MT1-MMP Activation Complex , 2000, The Journal of Biological Chemistry.

[2]  J. Becker,et al.  Coexpression of Integrin αvβ3 and Matrix Metalloproteinase-2 (MMP-2) Coincides with MMP-2 Activation: Correlation with Melanoma Progression , 2000 .

[3]  H. Birkedal‐Hansen,et al.  Inactivating Mutation of the Mouse Tissue Inhibitor of Metalloproteinases-2(Timp-2) Gene Alters ProMMP-2 Activation* , 2000, The Journal of Biological Chemistry.

[4]  P. Soloway,et al.  TIMP-2 Is Required for Efficient Activation of proMMP-2 in Vivo * , 2000, The Journal of Biological Chemistry.

[5]  D. Ruiter,et al.  Expression of integrin αvβ3 correlates with activation of membrane‐type matrix metalloproteinase‐1 (MT1‐MMP) and matrix metalloproteinase‐2 (MMP‐2) in human melanoma cells in vitro and in vivo , 2000 .

[6]  M. Bernardo,et al.  Binding of Active (57 kDa) Membrane Type 1-Matrix Metalloproteinase (MT1-MMP) to Tissue Inhibitor of Metalloproteinase (TIMP)-2 Regulates MT1-MMP Processing and Pro-MMP-2 Activation* , 2000, The Journal of Biological Chemistry.

[7]  Jeffrey W. Smith,et al.  Functional activation of integrin αvβ3 in tumor cells expressing membrane‐type 1 matrix metalloproteinase , 2000 .

[8]  M. Noguchi,et al.  Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas. , 1999, Cancer research.

[9]  A. Strongin,et al.  Remodeling of collagen matrix by human tumor cells requires activation and cell surface association of matrix metalloproteinase-2. , 1998, Cancer research.

[10]  H. Sato,et al.  Role of tissue inhibitor of metalloproteinases-2 (TIMP-2) in regulation of pro-gelatinase A activation catalyzed by membrane-type matrix metalloproteinase-1 (MT1-MMP) in human cancer cells. , 1998, Journal of biochemistry.

[11]  Y. Okada,et al.  TIMP-2 Promotes Activation of Progelatinase A by Membrane-type 1 Matrix Metalloproteinase Immobilized on Agarose Beads* , 1998, The Journal of Biological Chemistry.

[12]  S. Itohara,et al.  Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. , 1998, Cancer research.

[13]  D. Cheresh,et al.  Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity , 1998, Cell.

[14]  R. Fridman,et al.  Density‐dependent regulation of cell‐surface association of matrix metalloproteinase‐2 (MMP‐2) in breast‐carcinoma cells , 1998, International journal of cancer.

[15]  Gillian Murphy,et al.  The TIMP2 Membrane Type 1 Metalloproteinase “Receptor” Regulates the Concentration and Efficient Activation of Progelatinase A , 1998, The Journal of Biological Chemistry.

[16]  Y. DeClerck,et al.  Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) Binds to the Catalytic Domain of the Cell Surface Receptor, Membrane Type 1-Matrix Metalloproteinase 1 (MT1-MMP)* , 1998, The Journal of Biological Chemistry.

[17]  A. Strongin,et al.  Matrix metalloproteinase-2 activation modulates glioma cell migration. , 1997, Journal of cell science.

[18]  Jeffrey W. Smith,et al.  Identification of a Region in the Integrin β3 Subunit That Confers Ligand Binding Specificity* , 1997, The Journal of Biological Chemistry.

[19]  A. Strongin,et al.  Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. , 1997, Anticancer Research.

[20]  W. T. Chen,et al.  Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  P. Phillips,et al.  Localization and activation of type IV collagenase/gelatinase at endothelial focal contacts. , 1997, The American journal of physiology.

[22]  A. Strongin,et al.  A Novel Monoclonal Antibody, L1A3, Is Directed to the Functional Site of the αv Integrin Subunit , 1996 .

[23]  G. Butler,et al.  The Soluble Catalytic Domain of Membrane Type 1 Matrix Metalloproteinase Cleaves the Propeptide of Progelatinase A and Initiates Autoproteolytic Activation , 1996, The Journal of Biological Chemistry.

[24]  W. Stetler-Stevenson,et al.  Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3 , 1996, Cell.

[25]  M. Ramsby,et al.  Calibrating gelatin zymograms with human gelatinase standards. , 1996, Analytical biochemistry.

[26]  S. Weiss,et al.  Transmembrane-deletion Mutants of the Membrane-type Matrix Metalloproteinase-1 Process Progelatinase A and Express Intrinsic Matrix-degrading Activity (*) , 1996, The Journal of Biological Chemistry.

[27]  L. Liotta,et al.  Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. , 1996, Cancer research.

[28]  M. Seiki,et al.  Intermolecular Autolytic Cleavage Can Contribute to the Activation of Progelatinase A by Cell Membranes (*) , 1995, The Journal of Biological Chemistry.

[29]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[30]  E. Kohn,et al.  Molecular insights into cancer invasion: strategies for prevention and intervention. , 1995, Cancer research.

[31]  P. Chambon,et al.  Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[32]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[33]  Motoharu Seiki,et al.  A matrix metalloproteinase expressed on the surface of invasive tumour cells , 1994, Nature.

[34]  W. Stetler-Stevenson,et al.  Quantitative zymography: detection of picogram quantities of gelatinases. , 1994, Analytical biochemistry.

[35]  A. Strongin,et al.  Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. , 1993, The Journal of biological chemistry.

[36]  W. T. Chen,et al.  Binding and localization of M(r) 72,000 matrix metalloproteinase at cell surface invadopodia. , 1993, Cancer research.

[37]  L. Liotta,et al.  Extraction of type‐IV collagenase/gelatinase from plasma membranes of human cancer cells , 1990, International journal of cancer.

[38]  A. Eisen,et al.  Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[39]  I. Hart,et al.  Matrix metalloproteinases and metastatic cancer. , 1998, Biochemical Society symposium.

[40]  E. Ruoslahti,et al.  Integrin signaling and matrix assembly. , 1996, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[41]  L. Coussens,et al.  Matrix metalloproteinases and the development of cancer. , 1996, Chemistry & biology.